Elicio Therapeutics opened lower at $1.59, compared with its previous close of $1.63. In the last trading session, the stock traded between $1.55 and $1.65. It showed a downward intraday trend.
An investment of $100 made 4 years ago in Elicio Therapeutics is now worth
$ 8.58
Resulting in a loss of
$ 91.42 (91.42%)
Note: Past profits do not guarantee future returns.
Rating from 3 Analysts
Today's Change
$-0.07 (-4.48%)
Day High
$1.65
Day Low
$1.55
Day Open
$1.59
Prev Close
$1.63
Volume
1,64,060
1W Return
0.00%
1M Return
-17.36%
3M Return
-48.51%
6M Return
-86.59%
1Y Return
-83.13%
Market Cap ($ Mn)
44
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-211.94%
EPS (TTM)
$-0.28
1 Week
0.00%
1 Month
-17.36%
3 Months
-48.51%
6 Months
-86.59%
9 Months
-81.46%
HC Wainwright maintains Buy on Elicio Therapeutics, cuts target to $21
HC Wainwright & Co. maintains a Buy rating on Elicio Therapeutics. Price target lowered from $23 to $21 by analyst Robert Burns. No change to the overall investment recommendation.
2 days agoElicio Therapeutics to present at H.C. Wainwright conference
CEO Robert Connelly and CSO Pete DeMuth to speak at H.C. Wainwright conference. Fireside chat scheduled for September 14, 2026, at 2:00 pm ET in New York. Live webcast and replay available on company website for 90 days post-event. Lead program ELI-002 7P targets KRAS mutations in solid tumors.
2mo agoElicio Therapeutics to hold investor meetings at Wells Fargo conference
Elicio Therapeutics will hold one-on-one investor meetings on September 10, 2026. The sessions occur during the Wells Fargo 21st Annual Healthcare Conference in Boston. Lead program ELI-002 7P targets KRAS mutations present in roughly 25% of solid tumors. Pipeline includes candidates for BRAF-driven and p53 hotspot mutation cancers.
2mo agoElicio Therapeutics Q2 Results: EPS beats estimate, losses narrow 35% YoY
Elicio Therapeutics reported Q2 EPS of $(0.43), beating the $(0.54) estimate by 20.37%. Losses narrowed 34.85% YoY from $(0.66). The result signals improved operational performance against both historical benchmarks and current market expectations.
3mo agoElicio Therapeutics activates Phase 1 study for pancreatic cancer
Elicio Therapeutics has launched an investigator-initiated Phase 1 trial of ELI-002 7P in neoadjuvant pancreatic cancer, aiming to enroll 20 patients at Memorial Sloan Kettering. Funded by The Lustgarten Foundation and Break Through Cancer, the study combines the immunotherapy with chemotherapy and checkpoint inhibition to assess immune modulation and surgical outcomes. This follows data from the Phase 2 AMPLIFY-7P trial, where ELI-002 7P showed complete responses in metastatic cases, highlighting its potential to improve survival in high-risk patients.
3mo agoPomerantz investigates Elicio Therapeutics after Phase 2 trial failure
Pomerantz LLP is investigating Elicio Therapeutics for potential securities fraud following the company's announcement that its Phase 2 AMPLIFY-7P Study failed to meet its primary endpoint. The news caused Elicio's stock to plummet 70.96% on June 15, 2026. Investors are encouraged to contact the firm to discuss their legal rights.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 4 years ago in Elicio Therapeutics is now worth
$ 8.58
Resulting in a loss of
$ 91.42 (91.42%)
Note: Past profits do not guarantee future returns.
